Editas Medicine Announces Fourth Quarter and Full Year 2020 Results and Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Editas Medicine (EDIT) Reports Q4 Loss of $1.00/sh
February 25, 2021 7:55 AM ESTEditas Medicine (NASDAQ: EDIT) reported Q4 EPS of ($1.00), versus ($0.74) reported last year. Revenue for the quarter came in at $11.4 million, versus $12.3 million reported last year.
For earnings history and earnings-related data on Editas Medicine (EDIT) click here.
... More